<DOC>
	<DOC>NCT01513850</DOC>
	<brief_summary>The purpose of this study is to Evaluate the efficacy and safety of Hepabulin IV (HBIG, a study drug) after liver transplantation.</brief_summary>
	<brief_title>A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients</brief_title>
	<detailed_description>A 52-week, Multi-center, Open label, Single arm, Phase 3 Study to Evaluate the Efficacy and Safety of Hepabulin IV in HBsAg positive Liver Transplantation recipients</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>HBsAg Positive candidate for HBVrelated liver transplant Primary, single organ recipients written informed consent acute renal failure, Serum creatinin &gt;1.5*ULN severe cardiac disease or other significant disease HAV, HCV or HIV positive Immunoglobulin A deficiency. History of hypersensitivity to Human Immunoglobulin. History of cancer within 5 years. (without HCC) History of alcohol or/and drug abuse. History organ transplantation. Within 30 days, participation in another clinical trial and use of an investigational product. Subject suffer from any acute or chronic medical, surgical or psychiatric condition or laboratory abnormality that, may increase the risk associated with the study participation or investigational product administration, or may interfere with the interpretation of study result.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Liver Transplantation</keyword>
	<keyword>HBV</keyword>
	<keyword>HBV Recurrence</keyword>
	<keyword>HBsAg Positive</keyword>
</DOC>